What is Northland Capmk’s Forecast for BLFS FY2024 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Northland Capmk upped their FY2024 earnings estimates for BioLife Solutions in a research report issued to clients and investors on Wednesday, November 13th. Northland Capmk analyst C. Byrnes now expects that the medical equipment provider will post earnings of ($0.28) per share for the year, up from their prior estimate of ($0.47). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($0.15) EPS.

BLFS has been the subject of a number of other reports. Craig Hallum lifted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright dropped their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Northland Securities lifted their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

BioLife Solutions Stock Up 9.6 %

NASDAQ BLFS opened at $22.44 on Monday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a 1-year low of $11.91 and a 1-year high of $28.88. The company has a 50 day moving average of $23.92 and a 200-day moving average of $22.87. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -21.17 and a beta of 1.88.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its holdings in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the period. Geode Capital Management LLC lifted its holdings in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the period. State Street Corp lifted its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the period. Stifel Financial Corp lifted its holdings in BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 670 shares during the period. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions in the third quarter valued at $28,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares in the company, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Aby J. Mathew sold 17,604 shares of BioLife Solutions stock in a transaction on Monday, November 18th. The stock was sold at an average price of $20.05, for a total transaction of $352,960.20. Following the transaction, the executive vice president now owns 284,442 shares in the company, valued at approximately $5,703,062.10. This trade represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,644 shares of company stock worth $1,527,503. Company insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.